动静脉内瘘功能障碍的分子生物学机制研究进展

    Research advances in molecular mechanisms of arteriovenous fistula dysfunction

    • 摘要: 终末期肾病患者维持生命的重要方式是血液透析,血管通路是患者进行血液透析的首要条件,而动静脉内瘘(arteriovenous fistula,AVF)与其他通路方式相比有着感染率和并发症发生率较低的优点,是透析患者首选的血管通路方式,但是中国慢性肾脏病患者已超过1亿,这意味着慢性肾脏病已成为威胁中国居民健康的主要疾病之一。随着这一疾病患者的增多,终末期肾病患者也呈现逐年上升趋势。所以,AVF功能障碍发生率便随之增加了。目前,针对这一问题的临床有效治疗方法很少,对于导致AVF功能障碍的分子生物学研究也并不透彻。所以,本文就造成AVF功能障碍的分子生物学机制作一综述。

       

      Abstract: One important mode of maintaining life in patients with end-stage renal disease(ESRD) is hemodialysis. And vascular access has been a primary condition for hemodialysis. Offering the advantages of lower infection rate and complication rate as compared with other access modes, arteriovenous fistula(AVF) is the preferred vascular access mode in dialysis patients. However, there are currently more than 100 million chronic kidney disease(CKD) patients in China. Thus CKD has become one of the major diseases threatening domestic public health. Also there is an annually rising trend of ESRD along with a greater incidence of AVF dysfunction. Here molecular biological mechanisms of AVF dysfunction were summarized.

       

    /

    返回文章
    返回